Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 8;8(1):e11911.
doi: 10.2196/11911.

Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial

Christian Kromer  1 , Viktoria P Nühnen  1 , Wolfgang Pfützner  2 , Sebastian Pfeiffer  3 , Hans-Joachim Laubach  4 , Wolf-Henning Boehncke  4   5 , Joerg Liebmann  6 , Matthias Born  6 , Michael P Schön #  1   7 , Timo Buhl #  1   7
Affiliations

Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial

Christian Kromer et al. JMIR Res Protoc. .

Abstract

Background: Irradiation with visible blue light (wavelength 400-495 nm) is a promising, effective, and safe new treatment option for chronic inflammatory skin diseases such as psoriasis and atopic dermatitis.

Objective: We will perform a multicenter, placebo-controlled, double-blinded, 3-armed, prospective, randomized controlled trial to investigate the efficacy and safety of full-body blue light devices (wavelengths: 415 nm and 450 nm) compared with that of placebo irradiation for the treatment of atopic dermatitis.

Methods: We are planning to enroll a total of 150 patients at the University hospitals in Göttingen (Germany), Marburg (Germany), and Geneva (Switzerland).

Results: The trial was approved by the lead ethics committee of the medical faculty of the University of Göttingen (21/11/16). Further approvals were obtained from local and federal authorities (ethics committee Marburg, Cantonal Commission for Research Ethics Geneva, Suisse Medic, and Bundesinstitut für Arzneimittel und Medizinprodukte).

Conclusions: We will disseminate the results in a peer-reviewed journal.

Trial registration: ClinicalTrials.gov NCT03085303; https://clinicaltrials.gov/ct2/show/NCT03085303 (Archived by WebCite at http://www.webcitation.org/73ucqkkA1).

International registered report identifier (irrid): DERR1-10.2196/11911.

Keywords: atopic dermatitis; atopic eczema; blue light; irradiation; ultraviolet light.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: MB and JL are employees of Philips Light & Health.

Figures

Figure 1
Figure 1
Design of the FBB-CT01 device (415 nm and 450 nm). The patient lies on the treatment table and receives treatment from the light engine above.
See this image and copyright information in PMC

References

    1. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016 Mar 12;387(10023):1109–1122. doi: 10.1016/S0140-6736(15)00149-X. - DOI - PubMed
    1. Irvine AD, McLean WHI, Leung DYM. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011 Oct 06;365(14):1315–27. doi: 10.1056/NEJMra1011040. - DOI - PubMed
    1. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001 Feb;10(1):11–8. - PubMed
    1. Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10–9. doi: 10.1159/000245677. - DOI - PubMed
    1. Stalder J, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, Oranje A, Deleuran M, Cambazard F, Svensson A, Simon D, Benfeldt E, Reunala T, Mazereeuv J, Boralevi F, Kunz B, Misery L, Mortz CG, Darsow U, Gelmetti C, Diepgen T, Ring J, Moehrenschlager M, Gieler U, Taïeb A, PO-SCORAD Investigators Group Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011 Aug;66(8):1114–21. doi: 10.1111/j.1398-9995.2011.02577.x. - DOI - PubMed

Associated data